Aravive to Participate in Upcoming Virtual Investor Conferences in August
July 30 2020 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company
developing transformative therapeutics, today announced that the
Company will present and conduct one-on-one meetings at the
following three virtual investor conferences in August:
- William Blair Biotech Focus Conference on Thursday, August 6,
2020, at 10:00 a.m. ET
- BTIG Biotechnology Conference on Monday, August 10, 2020, at
9:30 a.m. ET
- Wedbush PacGrow Healthcare Conference on Tuesday, August 11,
2020, at 1:45 p.m. ET
Live webcasts and audio archives of the presentations will be
available at http://ir.aravive.com.
About AraviveAravive, Inc. (Nasdaq:
ARAV) is a clinical-stage oncology company developing
transformative treatments designed to halt the progression of
life-threatening diseases. Aravive’s lead product candidate,
AVB-500, is an ultra-high affinity decoy protein that targets the
GAS6-AXL signaling pathway. On July 23, 2020, Aravive announced the
successful completion of a Phase 1b trial of AVB-500 in platinum
resistant ovarian cancer and selection of the recommended Phase 2
dose. Analysis of all safety data to date showed that AVB-500 has
been generally well-tolerated with no dose-limiting toxicities or
unexpected safety signals. While the Phase 1b trial was a safety
trial and not powered to demonstrate efficacy, all 5 patients in
the 15 mg/kg cohort experienced clinical benefit, with 1 complete
response (CR), 2 partial responses, and 2 stable disease. Across
all cohorts, AVB-500 plus paclitaxel data showed an ORR of 35%
(8/23 patients, including 2 CRs). For more information, please
visit www.aravive.com.
Contacts: Media:Sheryl Seapy,
W2Osseapy@w2ogroup.com(949) 903-4750
Investors: Luke Heagle, W2O lheagle@w2ogroup.com (910)
726-1372
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024